GLP-1 Receptor Agonist Treatment and Health Outcomes in Methadone-Treated Patients with Opioid Use Disorder and Diabetes
People with opioid use disorder and diabetes taking GLP-1 drugs showed lower heart attack, depression, and suicidal thought rates alongside better addiction recovery.
In a large propensity-matched cohort of 2314 methadone-treated adults with OUD and type 2 diabetes, GLP-1 receptor agonist use was independently associated with lower rates of myocardial infarction (HR 0.58), hypoglycemia (HR 0.50), emergency visits, major depression (HR 0.71), and suicidal thoughts (HR 0.27), alongside a higher OUD remission rate (HR 1.75). These findings suggest GLP-1 RAs may provide simultaneous cardiometabolic, addiction, and psychiatric benefits in a high-risk underserved population, warranting prospective validation.
What the study was
- Study design
- Retrospective cohort with propensity score matching (TriNetX database)
- Population
- Adults on methadone maintenance with both OUD and T2D (HbA1c ≥6.5%), mean age 57.3 years; n=2314 after PSM
- Sample size
- 2314
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of General Internal Medicine
Why it surfaced
Novel application of GLP-1 RA in highly underserved OUD+T2D population showing multi-domain benefits (cardiometabolic + addiction + psychiatric) in a large PSM cohort. The OUD remission signal (HR 1.75) and suicidal ideation reduction (HR 0.27) are clinically striking and plausible given GLP-1 receptor expression in reward circuitry. J Gen Intern Med; calls for prospective RCT.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.